BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6430731)

  • 1. Pituitary and ovarian responses to LHRH stimulation in women with clinical features of the polycystic ovary syndrome.
    Heineman MJ; Thomas CM; Doesburg WH; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):273-84. PubMed ID: 6430731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
    de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal characteristics of women with clinical features of the polycystic ovary syndrome.
    Heineman MJ; Thomas CM; Doesburg WH; Rolland R
    Eur J Obstet Gynecol Reprod Biol; 1984 Jun; 17(4):263-71. PubMed ID: 6430730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of obesity and chronic hyperinsulinemia on gonadotropin release and gonadal steroid secretion in the polycystic ovary syndrome.
    Dunaif A; Mandeli J; Fluhr H; Dobrjansky A
    J Clin Endocrinol Metab; 1988 Jan; 66(1):131-9. PubMed ID: 2961783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of plasma gonadotropin and sex steroid release in polycystic ovarian disease after pituitary-ovarian inhibition with an analog of gonadotropin-releasing hormone.
    Calogero AE; Macchi M; Montanini V; Mongioi A; Maugeri G; Vicari E; Coniglione F; Sipione C; D'Agata R
    J Clin Endocrinol Metab; 1987 May; 64(5):980-5. PubMed ID: 3104389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of gonadotrophin-releasing hormone analogue (GnRH-A) administration on serum gonadotrophin and steroid levels in patients with polycystic ovarian disease.
    Mongioi A; Maugeri G; Macchi M; Calogero A; Vicari E; Coniglione F; Aliffi A; Sipione C; D'Agata R
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):228-34. PubMed ID: 3082098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of ovarian wedge resection on circulating gonadotropin and ovarian steroid levels in patients with polycystic ovary syndrome.
    Judd HL; Rigg LA; Anderson DC; Yen SS
    J Clin Endocrinol Metab; 1976 Aug; 43(2):347-55. PubMed ID: 950366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum bioactive and immunoreactive luteinizing hormone and follicle-stimulating hormone levels in women with cycle abnormalities, with or without polycystic ovarian disease.
    Fauser BC; Pache TD; Lamberts SW; Hop WC; de Jong FH; Dahl KD
    J Clin Endocrinol Metab; 1991 Oct; 73(4):811-7. PubMed ID: 1909705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome.
    White D; Leigh A; Wilson C; Donaldson A; Franks S
    Clin Endocrinol (Oxf); 1995 May; 42(5):475-81. PubMed ID: 7621565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist.
    Chang RJ; Laufer LR; Meldrum DR; DeFazio J; Lu JK; Vale WW; Rivier JE; Judd HL
    J Clin Endocrinol Metab; 1983 May; 56(5):897-903. PubMed ID: 6403570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary-ovarian response to the gonadotrophin-releasing hormone-agonist test in anovulatory patients with polycystic ovary syndrome: predictive role of ovarian stroma.
    Fulghesu AM; Angioni S; Belosi C; Apa R; Selvaggi L; Ciampelli M; Iuculano A; Melis GB; Lanzone A
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):396-401. PubMed ID: 16918963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease.
    Chang RJ; Mandel FP; Lu JK; Judd HL
    J Clin Endocrinol Metab; 1982 Mar; 54(3):490-4. PubMed ID: 6799536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of LH suppression in polycystic ovary syndrome.
    Fleming R; Black WP; Coutts JR
    Clin Endocrinol (Oxf); 1985 Dec; 23(6):683-8. PubMed ID: 3938353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accelerated 24-hour luteinizing hormone pulsatile activity in adolescent girls with ovarian hyperandrogenism: relevance to the developmental phase of polycystic ovarian syndrome.
    Apter D; Bützow T; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1994 Jul; 79(1):119-25. PubMed ID: 8027216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.
    Rittmaster RS; Thompson DL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):1096-102. PubMed ID: 2156885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adrenal and ovarian steroid hormone responses to gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Gonzalez F; Hatala DA; Speroff L
    Am J Obstet Gynecol; 1991 Sep; 165(3):535-45. PubMed ID: 1832519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which hormone tests for the diagnosis of polycystic ovary syndrome?
    Robinson S; Rodin DA; Deacon A; Wheeler MJ; Clayton RN
    Br J Obstet Gynaecol; 1992 Mar; 99(3):232-8. PubMed ID: 1296589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease.
    Steingold K; De Ziegler D; Cedars M; Meldrum DR; Lu JK; Judd HL; Chang RJ
    J Clin Endocrinol Metab; 1987 Oct; 65(4):773-8. PubMed ID: 3116031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.